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Abstract
Background: Hyaluronidases belong to a class of enzymes that degrade, predominantly, hyaluronan. These
enzymes are known to be involved in physiological and pathological processes, such as tumor growth, infiltration
and angiogenesis, but their exact role in tumor promotion or suppression is not clear yet. Advanced colorectal
cancer is associated with elevated amounts of hyaluronan of varying size. The aim of the present study was
therefore to illuminate the importance of hyaluronidases in colon carcinoma progression.
Methods: The patients’ samples (macroscopically normal and cancerous) were subjected to sequential extraction
with PBS, 4 M GdnHCl and 4 M GdnHCl - 1% Triton X-100. The presence of the various hyaluronidases in the
extracts was examined by zymography and western blotting. Their expression was also examined by RT-PCR.
Results: Among hyaluronidases examined, Hyal-1, -2, -3 and PH-20 were detected. Their activity was higher in
cancerous samples. Hyal-1 and Hyal-2 were overexpressed in cancerous samples, especially in advanced stages of
cancer. Both isoforms were mainly extracted with PBS. Hyal-3 was observed only in the third extract of advanced
stages of cancer. PH-20 was abundant in all three extracts of all stages of cancer. The expression of only Hyal-1
and PH-20 was verified by RT-PCR.
Conclusion: A high association of hyaluronidases in colorectal cancer was observed. Each hyaluronidase presented
different tissue distribution, which indicated the implication of certain isoforms in certain cancer stages. The results
provided new evidence on the mechanisms involved in the progression of colorectal cancer.
Background
Hyaluronan (HA) is a multifunctional high molecular
mass (HMM) glycosaminoglycan responsible for the
maintenance of the extracellular matrix (ECM) of con-
nective tissue. It is a simple linear glycosaminoglycan
(GAG) composed of repeating disaccharide units of D-
glucuronic acid and N-acetyl-D-glucosamine: [-b(1,4)-
GlcUA-b(1,3)-GlcNAc-]n. It is normally produced by
hyaluronan synthases (HAS1, HAS2, HAS3) at plasma
membrane and degraded extracellularly by the action of
plasma membrane hyaluronidases (Hyals) [1-3], endocy-
tosed, transferred to lysosomes where it is fully degraded
by the action of hyaluronidase, beta-glucuronidase and
beta-N-acetylglucosaminidase. Depending on the tissue
source, HA usually consists of 2,000-25,000 disaccharide
units, giving rise to molecular mass ranging from 10
6 to
10
7 Da [4,5]. Its lower molecular mass (LMM) forms
participate in a wide variety of biological functions.
HMM-HA is indicative of healthy tissues, while LMM-
HA seems to promote angiogenesis and activate signal-
ing pathways that are critical for cancer progression.
The LMM fragments could be truncated products of the
synthetic reaction, but could also be the result of hyalur-
onidase activity [6].
Due to its unique biophysical properties, HA contri-
butes directly to tissue homeostasis, interacts with link
proteins and proteoglycans (PGs) thus maintaining the
structural integrity of extracellular and pericellular
matrices, and its interaction with cell surface HA recep-
tors mediates crucial influences of HA on cell behavior.
Due to all of these functions, HA plays regulatory roles
in basic cellular behavior, such as cell adhesion, cell
migration, cell-cell recognition and cell differentiation
[7,8], and thus participates in many important processes
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several types of diseases, such as tumor growth and
atherosclerosis. Elevated extracellular amounts of HA
and its partially catabolized oligomers are correlated
with several types of malignancies potentially due to
decoupled synthesis and degradation [9,10].
Hyaluronidases (Hyals) are a class of enzymes that
degrade, predominantly, HA, and at a slower rate chon-
droitin and chondroitin sulphate. Hyals are endoglycosi-
dases that degrade the b-N-acetyl-D-glucosaminidic
linkages in HA chains [11]. In the human genome there
are six known genes coding for hyaluronidase-like
sequences, all having a high degree of homology, but
with different tissue distribution, namely hHyal-1
through -4, PH-20/Spam-1 and pseudogene Phyal1, that
is transcribed in the human genome but not translated.
Human Hyal-1 and Hyal-2 are the two major Hyals for
the degradation of HA in somatic tissues, hHyal-2
degrades high molecular mass HA to an approximately
20 kDa product, whereas Hyal-1 can degrade high mole-
cular mass HA to small oligomers, primarily to tetrasac-
charides [12]. A product of the human hyal-4 gene,
Hyal-4, based on preliminary studies, is also a chondroi-
tinase with a predominant activity toward Ch and ChS.
According to their pH activity profiles, they are divided
in two categories; Hyal-1, Hyal-2 and Hyal-3 are active
at acidic pH (pH 3.0-4.0) and are considered as acidic
Hyals [13], while PH-20 is a neutral active Hyal, as it is
active at pH 5.0-8.0 [14].
Hyals are known to be involved in biological processes
such as development and tumorigenesis [13,15]. Among
the six mammalian Hyals, Hyal-1 is the major tumor-
derived Hyal and is expressed by a variety of tumor
cells, confirmed with several methods (RT-PCR analysis,
cDNA cloning, protein purification, immunoblotting
and immunohistochemistry). In addition to Hyal-1, RT-
PCR analysis has revealed PH-20 expression in head and
neck carcinoma, especially laryngeal carcinoma [16,17].
Hyals levels are also shown to be elevated in breast
tumors and RT-PCR analysis has detected the expres-
sion of PH-20, Hyal-2 and Hyal-3 in breast cancer tis-
sues [18,19]. These observations suggest that Hyals
appear to be implicated in many carcinomas, however
the exact role of Hyals in colon cancer remains under
great concern.
Accumulating evidence has demonstrated that the pro-
duction of HA is excessive in malignant cancers;
increased HA serum levels and deposition in tumour tis-
sue are often associated with malignant progression in
colorectal cancer [20]. The purpose of this study was to
examine the activity and expression of Hyals in tissue
samples from patients with colorectal cancer and to iden-
tify different isoforms profile in different stages of cancer.
Methods
Chemicals
Phosphate buffer saline (PBS), phenylmethylsulfonyl
fluoride (PMSF), Alcian blue and Coomassie Brilliant
blue were obtained from Serva (Darmstadt, Germany).
Hyaluronic acid, hyaluronidase (type I) from bovine
testes, benzamidine hydrochloride, ε-amino-n-caproic
acid, Triton X-100, N-ethylmaleimide (NEM) and ethy-
lenediaminetetracetic acidd i s o d i u ms a l td i h y d r a t e
(Na2EDTA) were obtained from Sigma. Mouse polyclo-
nal antibodies against hyaluroglucosaminidase 1 (Hyal-
1), hyaluroglucosaminidase 3 (Hyal-3) and sperm
adhesion molecule 1 (PH-20/Spam-1) were obtained
from Abnova Corporation (Taiwan). RNA extraction kit
(Nucleospin RNA II) was from Macherey-Nagel. Prime-
Script™one step RT-PCR kit and 100 bp DNA ladder
were obtained from TakaRa BIO INC. All other chemi-
cals used throughout the study were of the highest
available grade.
Tissue source
Macroscopically normal and cancerous tissues were
obtained from 34 patients (8 females and 26 males, age
range 45-90), who underwent surgical operation due to
colorectal carcinoma at the Surgical Clinic of the Gen-
eral University Hospital of Patras, Greece. The patients
included in the study were healthy until the time of
diagnosis of colorectal cancer, without any other disease.
Surgical procedures consisted of different types of color-
ectal resection. Two specimens were obtained from each
patient, one from the center of the tumor and the other
of similar weight from areas adjacent to the cancerous
regions (macroscopically normal areas), and were stored
at -80°C for further biochemical examination. Clinical
information was obtained after clinical and pathological
diagnosis of the patients: sex, age, location of primary
tumor, pathological differentiation, distant metastasis
and radiation therapy (Table 1). The clinical stage of all
tumors was completed according to TNM and Astler-
Coller (A/C) classification. The study design was
approved by the Ethical Committee of the University
Hospital of the University of Patras and informed con-
sent was obtained from all patients before entry into the
study.
Extraction and Zymographic examination of Hyals
Parts of macroscopically normal and cancerous tissues
were used for the detection of Hyals. Each specimen
was finely diced and the macromolecules contained
were sequentially extracted for 3 × 24 h periods at 4°C
in the dark with PBS (10 mM disodium phosphate,
0.14 M NaCl, pH 7.4), 4 M GdnHCl - 0.05 M sodium
acetate and 4 M GdnHCl - 0.05 M sodium acetate
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per g of tissue [21]. This three-step extraction proce-
dure was applied to permit the differential extraction
of Hyals isoforms, since accumulated evidence suggests
that they are present in either soluble or membrane-
bound form [11,12]. A protease inhibitor cocktail was
included containing 5 mM benzamidine hydrochloride,
0.4 mM phenylmethylsulfonyl fluoride, 10 mM N-
ethylmaleimide, 0.1 M ε-amino-n-caproic acid and 0.01
MN a 2EDTA. Each one of the extracts was stored at
-20°C until use.
Hyaluronidase activity of the various extracts was
examined using a HA zymography procedure, as
described previously [22-24]. The samples were electro-
phoresed and at the end of the electrophoresis the gel
was submerged in the suitable buffer (0.15 M NaCl-0.1
MC H 3COONa pH 3.7) and incubated at 37°C for 16 h.
Then the gel was stained sequentially with Alcian blue
to stain undegraded HA and with Coomassie blue to
overstain the Alcian blue stained HA and the non enzy-
mic protein bands. The enzyme activity appeared as
white bands in a dark blue background. Finally, semi-
quantification of the enzymatic units was achieved after
scanning of the gel by a digital scanner.
Western Blotting identification of Hyaluronidases
The various extracts were subjected to SDS-PAGE (T:
10%, C: 2.7%) according to Laemmli [25], using denatur-
ing conditions in the presence of b-mercaptoethanol.
After electrophoresis, the gels were immersed in 0.15 M
iodoacetamide in 0.05 M Tris-HCl pH 8.3 for 15 min at
room temperature to block free b-mercaptoethanol.
Thereafter, the protein bands were electrotransferred to
nitrocellulose (Immobilon NC) membranes at constant
current of 80 mA at 4°C for 20 h in 0.05 M Tris-HCl
pH 8.3. The membranes were washed with PBS contain-
ing 0.1% Tween 20 (PBS-T) and blocked with 5% dry
skimmed milk in PBS-T. They were then incubated with
the respective polyclonal antibody (against either Hyal-1,
Hyal-2, Hyal-3 or PH-20) in an appropriate dilution in
PBS-T for 1 h at room temperature. After repeated
washings with PBS-T, the membranes were incubated
with second antibody (goat anti-mouse IgG) peroxidase-
conjugated (1:5000) in PBS-T, for 1 h at room tempera-
ture and washed exhaustively with PBS-T. The
immunoreacting bands werev i s u a l i z e db ye n h a n c e d
chemiluminescence method (ECL), according to the
manufacturer’s instructions and by exposure to Agfa
Curix X-ray film.
RNA extraction and RT-PCR analysis
Colorectal specimens were pulverized in liquid nitro-
gen and subjected to total RNA extraction, using the
Nucleospin extraction kit, as described by the manu-
facturer and treated with RNase-freeDNase to remove
contaminating genomic DNA. Strand cDNA was
synthesized from 40 ng of total RNA in 50 μl reaction
components for one-step RT-PCR kit, according to the
manufacturer’s instructions. This reaction mixture con-
tained in addition 1 μMo ft h es e n s ea n da n t i s e n s ep r i -
mers showed in Table 2. The amplification was
performed in a GeneAmp 2400 thermal cycler (Perkin-
Elmer Co.) and the reaction profile used for all primers
sets was: 95°C for 10 min for the activation of DNA
polymerase and then 25-35 cycles, depending on the
Table 1 Characteristics of patients with colon cancer
Case no. Age Sex Loc
1 Hist. features
2 A/C stage
3
1 59 M S - Tis
2 66 M C - Tis
3 61 M R - Tis
4 72 F T Well A
5 90 M R Poor B1
6 76 M S Med B1
7 56 M R Med B1
8 54 F S Well B1
9 74 F S Med B2
10 73 M D Med B2
11 84 F D Med B2
12 81 M R Poor B2
13 66 M C Med B2
14 74 M S Well B2
15 77 M S Med B2
16 79 M C Med B2
17 45 M T Med B2
18 58 M S Med B2
19 60 F R Med C1
20 82 F R Med C1
21 65 M C Med C1
22 59 M R Med C1
23 68 F R Med C1
24 78 M S Med C2
25 87 M R Med C2
26 71 M R Med C2
27 72 M A Poor C2
28 57 M S Med C2
29 61 M A Med C2
30 50 M R Med C2
31 80 M C Med C2
32 80 F A Poor C2
33 72 M S Med D
34 75 M A Poor D
The patients have been classified according to the stage of cancer.
1Location (of primary tumor); A: ascending colon; C: cecum; D: descending
colon; R: rectum; S: sigmoid colon; T: transverse colon.
2Histological features (Grade of differentiation); well: well differentiated; mod:
moderately well differentiated; poor: poorly differentiated.
3A/C stage; Astler-Coller classification of tumors. - represents non cancerous
samples (adenoma tissues).
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10 min to finalize extension. The number of cycles was
chosen so that reactions could be terminated during
the linear phase of amplification. The reaction pro-
ducts were separated by electrophoresis in 2% (w/v)
agarose gels contained Gelstar Stain to visualize the
amplified cDNA fragments under UV. The gels were
then scanned and the bands were analyzed densitome-
trically. Quantitative differences between cDNA sam-
ples were normalized by including GAPDH in all
experiments.
Statistical analysis
Statistically significant differences in the detection of
Hyals between healthy, macroscopically normal and can-
cerous tissues, were executed by students’ t-test, using
the microcal origin software. Significance was deter-
mined at values of P < 0.05.
Results
Hyaluronidase activity of tissue extracts in colon cancer
The sequential extracts from the various specimens were
subjected to hyaluronan zymography in acidic condi-
t i o n s .I nt h em a j o r i t yo fs a m p l e so n el y s i sb a n dw a s
observed corresponding to 72 kDa. In minor number of
samples, bands of smaller molecular mass (20-40 kDa)
were also identified (not shown). These samples were of
advanced stages of cancer (stages B and C). Semi-quan-
titative analysis of the zymograms revealed increased
hyaluronidase activity in cancerous PBS tissue extracts
compared to the macroscopically normal PBS extracts
(fig. 1A), in all anatomic sites examined (not shown).
Both activities were significantly increased compared to
intact, healthy tissues (fig. 1B).
Hyaluronidase activity was significantly elevated in
cancerous specimens compared to macroscopically nor-
mal ones in all anatomic sites examined (fig. 2A). Espe-
cially in the case of sigmoid and cecum, an increase of
about 80 and 100% was calculated, whereas the increase
was much smaller in the other anatomic sites. In addi-
tion, hyaluronidase activity seemed to vary with the
stage of cancer. The highest activity was observed at
early stages (Tis/A), as well as at stage D of cancer and
Table 2 Sequences of oligonucleotide primers for RT-PCR
analysis
Primer Sequence (5’-3’ direction) Product length
(bp)
Hyal-1
(forward)
CATATTGAGAACCTAATGCACTCTG 208
Hyal-1
(reverse)
GGAATGAATGGTGTCTGCTGTGG
Hyal-2
(forward)
TTGTGAGCTTCCGTGTTCAG 217
Hyal-2
(reverse)
GTCTCCGTGCTTGTGGTGTA
PH-20
(forward)
GAGTTGTAAGGAGAAAGCTGAT 194
PH-20
(reverse)
TGGCTACAGAAGAAATGATAAGAAACA
GAPDH
(forward)
TCAACGGATTTGGTCGTATTGGG 270
GAPDH
(reverse)
GACTCCACGACGTACTCAGC
Figure 1 Hyaluronidase extractability. A. Up. Typical hyaluronan zymography pattern of the three sequential extracts of the samples,
macroscopically normal (N) and cancerous (C) of patients with colorectal cancer. The extracts are PBS (1), 4 M GdnHCl (2) and 4 M GdnHCl - 1%
Triton X-100 (3). Down. Semi-quantitative representation of the zymography experiments. B. Up. Hyaluronidase activity in PBS extracts from
healthy subjects (H), macroscopically normal (N) and cancerous (C) specimens of patients. Down. Semi-quantitative representation of the
zymography experiments. The arrow indicates the migration of the main lysis band.
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activity was also related to the grade of cancer, being
obvious in cancerous samples (fig. 2C), whereas the
macroscopically normal samples seemed to contain
about the same activity of the enzyme.
Western blotting analysis was further used for the
identification of Hyal(s) present in the sequential
extracts. In all tissue samples examined, Hyal-1, Hyal-2,
Hyal-3 and PH-20 were found to exist, each one
observed in different extracts and different stages of
cancer. Hyal-1 was overexpressed in cancerous samples
than in macroscopically normal ones, mainly in
advanced stages of cancer (fig. 3A). Hyal-2 was
expressed, but not in large amounts, in tissue samples of
patients with advanced stage (B and C) of cancer (fig.
3B). Both Hyal-1 and Hyal-2 were mainly, if not exclu-
sively, extracted with PBS. On the other hand, Hyal-3
was observed only in 4 M GdnHCl-1% Triton X-100
extracts of advanced stages of cancer (fig. 3C). PH-20
was abundant in all three extracts of different stages of
cancer; in PBS extracts PH-20 was detected mainly in
cancerous samples (fig. 3D), but in 4 M GdnHCl and
4 M GdnHCl-1% Triton X-100 extracts was mainly
detected in macroscopically normal samples.
RT-PCR analysis of hyaluronidase transcripts in colon
cancers
Hyaluronidases expression in tissue was also examined
by RT-PCR analysis (fig. 4). The results indicated that
Hyal-1 was overexpressed in cancerous samples com-
pared to macroscopically normal ones. Semi-quantitative
analysis of the results revealed increased Hyal-1 expres-
sion especially in B2, C1 and C2 stage of cancer (fig.
4A). PH-20 was overexpressed at early stages of cancer,
especially in the cancerous samples; considerable expres-
sion was also observed in benign tumors (fig. 4B). Hyal-
2 and -3 expression at the mRNA levels was not identi-
fied at any of the samples examined. Additional exami-
nations, regarding any mutations of the genes or
alternative splicing of mRNA have not been performed.
Discussion
A large amount of studies shows that hyaluronan
deposition is up-regulated in most malignancies. Espe-
cially in human cancers, hyaluronan concentrations are
usually higher in cancerous than in normal tissues.
Colon cancer, among other kinds of cancer, is consid-
ered to enriched with hyaluronan [6,26]. In that kind of
tumor, hyaluronan may support tumor growth by stimu-
lating anchorage-independent growth and proliferation
of tumor cells. Moreover, hyaluronan may also actively
promote tumor cell adhesion, migration and metastasis
and may also protect against immune surveillance [27].
Additionally, tumor cells may take advantage of hyaluro-
nan-rich extracellular matrices to invade more easily
into the surrounding tissues.
Based on these observations, in this work we investi-
gated the activity and the expression of hyaluronidases
in tissue samples from patients with colon cancer, for
clarifying the dependence of hyaluronan catabolism on
individual hyaluronidase activities under pathological
Figure 2 Quantification of hyaluronidase activity.S e m i -
quantitative analysis of hyaluronidase in colon cancer after
zymography of PBS extracts according to: (A) anatomic site, (B)
stage of cancer, and (C) grade of cancer.
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as tumor inhibitors in vivo [28], Hyal-1 reversibly corre-
lates with hyaluronan content [29] and that Hyal-1 cor-
relates with tumor grade, stage, and multifocality
[17,30]. The results of our study indicated that hyaluro-
nidases were involved in colon cancer progression.
Sequential extraction of hyaluronidases from the various
specimens was applied in the study to obtain an idea on
their localization, since PBS would extract enzyme iso-
forms freely available within the tissue, 4 M GdnHCl
would extract enzyme isoforms entrapped in or inter-
acted with macromolecular aggregates and Triton-X
would extract membrane bound or intracellularly loca-
lized enzyme isoforms.
Figure 3 Western blotting analysis of hyaluronidases. A. Hyal-1 in macroscopically normal (N) and cancerous (C) PBS extracts of A, C1 and
C2 stages of cancer. B. Hyal-2 in macroscopically normal (N) and cancerous (C) PBS extracts of B and C stages of cancer. C. Hyal-3 in
macroscopically normal (N) and cancerous (C) 4 M GdnHCl-1% Triton X-100 extracts of B2, C1 and C2 stages of cancer. D. PH-20 in
macroscopically normal (N) and cancerous (C) samples of B2, C1 and C2 stages of cancer; left; PBS extracts, middle; 4 M GdnHCl extracts and
right; 4 M GdnHCl-1% Triton X-100 extracts. The arrows indicate the migration of the main immunoreacting band.
Figure 4 RT-PCR analysis of hyaluronidases. A. Up. cDNA product of Hyal-1 (208 bp) in macroscopically normal (N) and cancerous (C) samples
from different patients. Down. Semi-quantitative representation of the results. B. Up. cDNA product of PH-20 (194 bp) in macroscopically normal
(N) and cancerous (C) samples from different patients. Down. Semi-quantitative representation of the results. The arrows indicate the migration
of cDNA products of GAPDH and hyaluronidases.
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observed in PBS extracts, compared to 4 M GdnHCl
and 4 M GdnHCl-1% Triton X-100 extracts. About 50%
of the enzyme activity was extracted with PBS from the
macroscopically normal specimens, and more than 60%
from the cancerous. This observation suggested that
hyaluronidases were not tightly bound to the tissue or
the cells. By comparing the total hyaluronidase activity
in healthy colon, and in macroscopically normal and
cancerous specimens of colorectal carcinoma samples, it
was found to be elevated up to 100% in cancerous speci-
mens compared to both others.
Statistical analysis of the results obtained from hyalur-
onan zymography revealed that hyaluronidase activity
was related to the stage and grade of cancer. Specifically,
at early stages high hyaluronidase activity was observed,
and after stage B2 the enzymatic activity declined, how-
ever it increased at very late stages. These results
implied that hyaluronidases in the onset of pathological
conditions tended to create small fragments of hyaluro-
nan that help tumor progression. It would be interesting
to identify the size distribution of hyaluronan at early
stages of cancer, since it is well reported that hyaluro-
nan of small molecular mass is present in cancer
[31,32].
On the other hand, high molecular mass hyaluronan
induces tissue hydration and therefore it physically cre-
ates spaces through which tumor cells migrate and
invade, and this might be the explanation of the
decreased hyaluronidase activity after the early stages.
The increase of the activity at late stages of cancer may
be required for the final degradation and the removal of
the ECM components sensitive to the enzyme. Of
course, it is not only hyaluronidases activity, but hyalur-
onan synthases activity that plays also important role in
hyaluronan size and therefore in tumor progression and
this is another point of inerest. A third point requiring
clarification is concerning to the presence of highly
expressing CD44 cells, being an additional significant
factor related to hyaluronan that affects tumor
progression.
As far as it concerns the grade of cancer it seemed
that there was no significant differences neither between
macroscopically normal samples of poor, moderately
and well differentiated specimens nor between cancer-
ous ones. Nevertheless, cancerous specimens contained
50-80% more hyaluronidase activity than macroscopi-
cally normal.
Using Western Blotting analysis, we managed to clear
up the involvement of individual hyaluronidases existing
in certain parts of the tissue; normal and cancerous.
The hyaluronidases existing in samples were Hyal-1, -2,
-3 and PH-20. It seemed that at early stages of tumor
growth PH-20 was the most abundant extracellularly, as
it was extracted mainly with PBS. At advanced stages it
seemed that Hyal-1, -2 and PH-20 had a collaborating
action for fragmention of hyaluronan. The above hyalur-
onidases didn’t act just extracellularly, but also had a
transmembrane action, since they appeared in PBS and
4 M GdnHCl extracts. The late stages of cancer (C2
and D) seemed to prefer mostly the synergistic action of
Hyal-1, PH-20 and Hyal-3. The last one seemed to be
localized entirely in cell membrane as it was present
only in 4 M GdnHCl-1% Triton X-100 extracts. How-
ever, it remained unclear at what point the fragmenta-
tion of hyaluronan switched from an extracellular or
cell surface process to an endosomal or lysosomal pro-
cess and might be due to the energy demands of the
cancer cells. In addition, the factors regulating the dif-
ferential expression of hyaluronidase isoforms are not
known, although it has been proposed growth factors
may have such effect [33] and Hyal-1 is regulated epi-
genetically [34].
Conclusions
The metabolic pathways for hyaluronan degradation are
highly ordered, composed of carefully controlled reac-
tions that rely on regulation of individual enzyme activ-
ities. From our work hyaluronidases seemed to play
different tissue distribution role in colon cancer, with a
combining action of these isoenzymes in colon cancer
progression. Understanding the mechanisms of hyaluro-
nidases involved in colon cancer progression may be a
useful tool for future prognosis of colon cancer. How-
ever, how such regulation and mechanisms are accom-
plished needs to be clarified.
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